Stage III Thyroid Gland Papillary Carcinoma
3 clinical trials · Condition
◉ Watch Stage III Thyroid Gland Papillary Carcinoma
| Record | Firm | Date |
|---|---|---|
| Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (NCT01811212) | National Cancer Institute (NCI) | 2013-05-08 |
| Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (NCT00729157) | National Cancer Institute (NCI) | 2008-08-01 |
| Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine (NCT00559949) | National Cancer Institute (NCI) | 2007-12-01 |
Track Stage III Thyroid Gland Papillary Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.